Reuters logo
BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196
September 19, 2017 / 11:44 AM / in a month

BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196

Sept 19 (Reuters) - Madrigal Pharmaceuticals Inc

* Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia

* Top-line results from NASH expected late 2017 and HEFH early 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below